Drug profile · INN
nipocalimab
IMAAVY
nipocalimab (IMAAVY) is a igg receptor fcrn large subunit p51 antagonist.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AL03
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — nipocalimab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
nipocalimab (IMAAVY) is a igg receptor fcrn large subunit p51 antagonist.
Key facts
INN nipocalimab
Brand IMAAVY
Mechanism IgG receptor FcRn large subunit p51 antagonist
Target IgG receptor FcRn large subunit p51
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AL03
Mechanism of action
IgG receptor FcRn large subunit p51 antagonist
Primary target: IgG receptor FcRn large subunit p51
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nipocalimab?
nipocalimab (IMAAVY) is a igg receptor fcrn large subunit p51 antagonist.
What is the brand name for nipocalimab?
IMAAVY is a marketed brand name for nipocalimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.